Abbott Laboratories stock falls 2.70 percent and underperforms competitors

13 articles · Updated · MarketWatch · Apr 29

Abbott Laboratories shares closed at $91.33 on Wednesday, dropping 2.70% and snapping a two-day winning streak.
The stock underperformed rivals as Johnson & Johnson fell 0.19%, Pfizer slipped 0.83%, and Merck rose 0.84% during a generally weak market session.
Abbott shares are now 34.32% below their 52-week high of $139.06, with trading volume at 9 million, below the 50-day average of 11.6 million.

With patient deaths linked to its top device, can Abbott's 54-year dividend growth streak survive?

Abbott slashed its profit forecast after a $23 billion deal. A smart move or a costly mistake?

Analysts call Abbott a 'buy,' but are they ignoring the company's critical product safety warnings?

After a $495M lawsuit and a major product recall, is Abbott facing a systemic crisis of trust?

Is the FDA's most serious recall a sign of deeper, systemic quality control failures at Abbott?